Postoperative Pain Control With Lipossomic Extended Release Bupivacaine
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer, Post-Surgical Pain |
| Therapuetic Areas: | Musculoskeletal, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/22/2018 |
| Start Date: | July 9, 2015 |
| End Date: | October 31, 2018 |
| Contact: | Benny Weksler, MD |
| Email: | bweksler@uthsc.edu |
| Phone: | 901-448-2918 |
Randomized Trial Comparing Bupivacaine vs Lipossomic Extended Release Bupivacaine for Postoperative Pain Control After Minimally Invasive Thoracic Surgery
Randomized trial of intraoperative intercostal block with bupivacaine with epinephrine
compared to lipossomal extended release bupivacaine.
compared to lipossomal extended release bupivacaine.
Patients undergoing minimally invasive thoracic surgery will be randomized to receive 0.05%
bupivacaine with 1:200,000 epinephrine (control group) or extended release lipossomal
bupivacaine. Primary outcomes are postoperative pain measured by visual analog scale, amount
of morphine equivalent narcotics used, and postoperative complications. Patients are excluded
if they undergo open thoracotomy, or minimally invasive decortication.
bupivacaine with 1:200,000 epinephrine (control group) or extended release lipossomal
bupivacaine. Primary outcomes are postoperative pain measured by visual analog scale, amount
of morphine equivalent narcotics used, and postoperative complications. Patients are excluded
if they undergo open thoracotomy, or minimally invasive decortication.
Inclusion Criteria: Patients who will be undergoing minimally invasive thoracic surgery
- Patients who will be undergoing minimally invasive thoracic surgery
Exclusion Criteria:
- Open surgery
- Chronic use of narcotics
- Use of pregabalin or similar
- Significant liver or kidney dysfunction
We found this trial at
1
site
Click here to add this to my saved trials
